Conduit Pharmaceuticals (NASDAQ:CDT), is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets. The Company has developed a unique business model that allows it to act as a conduit to advance Phase 1 clinical assets from pharmaceutical companies through Phase 2, to develop new treatments for patients. Our novel approach addresses unmet medical needs and lengthens the intellectual property for our existing assets through cutting-edge solid-form technology, and then aims to commercialize these products with life science companies.
The Company’s current development pipeline, following the recently completed License Agreement with AstraZeneca PLC (NASDAQ:AZN) dated August 7, 2024, includes two HK-4 Glucokinase Activators which have undergone 20+ Phase I trials in over 1,000 patients and have been determined to be Phase 2 ready for application in autoimmune disorders, as well as the Company’s proprietary, patent pending in some jurisdictions, solid-form compound targeting autoimmune disorders. The Company’s development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has been licensed in, and has the potential to treat idiopathic male infertility.
Conduit is led by our highly experienced team of pharmaceutical executives, including Founder and CEO, Dr. David Tapolczay, former Chief Executive Officer of UK-based medical research charity LifeArc; and the Chair of our Board, Dr. Freda Lewis-Hall, former Chief Medical Officer of Pfizer, Inc. (NYSE:PFE).